Ascendis Pharma AS (MEX:ASNDN) EPS (Basic): MXN-47.03 (TTM As of Mar. 2026)


MEX:ASNDN Ascendis Pharma AS MEX:ASNDN
37 GF Score
Price MXN3,851.44
! 1 Warning Sign
View Full Analysis

What is Ascendis Pharma AS EPS (Basic)?

Ascendis Pharma AS MEX:ASNDN 37 EPS (Basic) is MXN-47.03 as of Mar. 2026. GuruFocus rates MEX:ASNDN with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

Ascendis Pharma AS's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was MXN0.00. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-47.03.

Ascendis Pharma AS's EPS (Diluted) for the three months ended in Mar. 2026 was MXN0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-50.94.

Ascendis Pharma AS's EPS without NRI for the three months ended in Mar. 2026 was MXN0.00. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -28.22.

During the past 3 years, the average EPS without NRI Growth Rate was 31.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 14.00% per year. During the past 10 years, the average EPS without NRI Growth Rate was -11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Ascendis Pharma AS's highest 3-Year average EPS without NRI Growth Rate was 31.40% per year. The lowest was -68.10% per year. And the median was -28.30% per year.

Ascendis Pharma AS  (MEX:ASNDN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Ascendis Pharma AS EPS (Basic) Related Terms

Ascendis Pharma AS EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS EPS (Basic) Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -162.26 -214.79 -158.27 -142.61 -79.28

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.95 -13.90 -21.53 -11.60 0.00
MEX:ASNDN
37GF Score
Ascendis Pharma AS MEX:ASNDN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Ascendis Pharma AS's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4807.859-0)/60.607
=-79.33

Ascendis Pharma AS's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(13119.863-0)/61.393
=213.70

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-47.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of MXN-47.03 mean?
Ascendis Pharma AS (MEX:ASNDN) has a EPS (Basic) of MXN-47.03 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's EPS (Basic) too high?
Ascendis Pharma AS's current EPS (Basic) is MXN-47.03. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's EPS (Basic) compare to SMMT and BBIO?
Ascendis Pharma AS's EPS (Basic) of MXN-47.03 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current EPS (Basic) is MXN-47.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (MEX:ASNDN) has a current EPS (Basic) of MXN-47.03. The current EPS (Basic) is MXN-47.03. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Ascendis Pharma AS (MEX:ASNDN), the current EPS (Basic) is MXN-47.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges ASND:USA
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for MEX:ASNDN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN3,851.44
Price